<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391924</url>
  </required_header>
  <id_info>
    <org_study_id>NR 98-2-301</org_study_id>
    <nct_id>NCT00391924</nct_id>
  </id_info>
  <brief_title>Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome</brief_title>
  <official_title>Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Arthritis Association</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine whether dehydroepiandrosterone (DHEA) administration
      improves fatigue and general well-being in patients with systemic lupus erythematosus or
      primary Sjögren's syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue and reduced general well-being are frequent complaints in patients with the chronic
      autoimmune disorder systemic lupus erythematosus (SLE) or primary Sjögren's syndrome (pSS).
      Uncontrolled studies suggested that the administration of dehydroepiandrosterone (DHEA) may
      improve such complaints. The aim of our randomized double-blind placebo-controlled study is
      to examine the effect of daily oral 200 mg DHEA on fatigue, well-being, and functioning in
      women with SLE or pSS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>January 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General fatigue</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Depressive mood</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental well-being</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical functioning</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>(all measures at baseline, after 3, 6, and 12 months of intake of study medication, and 6 months after cessation of medication intake)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported pain,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia tender points</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobulin-G</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported ocular dryness (in pSS only)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported oral dryness (in pSS only)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular tear production (in pSS only)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLE disease activity index (in SLE only)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (in SLE only)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of glucocorticoids (in SLE only)</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Sjogren's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pSS with a focus score &gt;= 1 on minor salivary gland biopsy and fulfilling European
             classification criteria (Ann Rheum Dis 1996;55:116-21)

          -  SLE according to ACR classification criteria (Arthritis Rheum 1982;25:1271-7)

          -  Willingness to apply effective contraception (premenopausal women)

          -  Written informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Pregnancy wish

          -  Serum creatinine &gt; 150 µmol/L

          -  Glucocorticoid use at a daily dose &gt; 10 mg prednisone (or equivalent)

          -  Cyclophosphamide treatment in the preceding year

          -  Hyper- or hypothyroidism

          -  History of malignancy within the previous 5 years with exception of squamous or basal
             cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald HW Derksen, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 2004 Nov;50(11):3591-5.</citation>
    <PMID>15529389</PMID>
  </results_reference>
  <results_reference>
    <citation>Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2004 Oct;63(10):1335-7.</citation>
    <PMID>15361396</PMID>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <last_update_submitted>October 24, 2006</last_update_submitted>
  <last_update_submitted_qc>October 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2006</last_update_posted>
  <keyword>Dehydroepiandrosterone</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Lupus Erythematosus, Systemic</keyword>
  <keyword>Sjogren's Syndrome</keyword>
  <keyword>Bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

